CoChat
Sign Up
Cited by 3

Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan

Ikka, Tsunakuni, Fujita, Misao, Hatta, Taichi, Isobe, Tetsu, Konomi, Kenji, Onishi, Tatsuo, Sanada, Shoji, Sato, Yuichiro +2 more·2023·Stem Cell Reports
DOI 10.1016/j.stemcr.2023.04.006
Open this paper in CoChat — free account

Abstract

(Stem Cell Reports 18, 613–617; March 14, 2023) The authors have changed all references to “Whitelist” in the supplemental information to the term “DOAJ or Web of Science.” The reason for the change was to use a more socially fair and neutral term that does not contain discriminatory meanings or misinterpretations. Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in JapanIkka et al.Stem Cell ReportsFebruary 23, 2023In BriefWe outlined five studies regarding the quality of the review by committees based on the Act on the Safety of Regenerative Medicine. The findings raise serious concerns about the independence, integrity, and quality of reviews of therapeutic plans by these committees with inappropriately close relationships to medical institutions and companies. Full-Text PDF Open Access

Integrity signals

Registry

Crossref · 10.1016/j.stemcr.2023.04.006

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The ASRM applies to medical treatments that intend to use cell-processed products, and applicable clinical trials are reviewed by certified committees for RM or the Certified Special Committee for Regenerative Medicine accredited by MHLW.

    “The ASRM applies to medical treatments that intend to use cell-processed products (Article 2).”

    From Brief summary of the regulatory frameworks of regenerative medicine therapies (2025) · cites this paper as Ikka et al., 2023

Cited by

Sorted by citations

Authors
Ikka, T., Fujita, M., Hatta, T., Isobe, T., Konomi, K., Onishi, T., Sanada, S., Sato, Y., Tashiro, S., & Tobita, M.
Venue
Stem Cell Reports
Publisher
Elsevier BV
Published
2023-05
Volume
18
Issue
5
Pages
1247
ISSN
2213-6711
DOI
10.1016/j.stemcr.2023.04.006
Cited by
3
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review